论文部分内容阅读
用胆酸钠增溶、硫酸铵盐析、差速离心及免疫亲和层析法从甲状腺细胞膜成分中提纯ｈＴＰＯ，纯化ｈＴＰＯ的比生物活性提高了４３８．７倍，其ＲＺ值为０．２５．ＳＤＳ－ＰＡＧＥ于１０５ＫＤ和１０７ＫＤ处呈现两条条带。以固相Ｉｏｄｏｇｅｎ法标记ｈＴＰＯ，建立放免法测定２９例ＡＩＴＤ患者ＭｃＡｂ阳性血清的ＴＰＯＡｂ结合率为１６．３％±６．３％，而１１例正常人ＭｃＡｂ阳性血清的结合率为３．４％１４．７％，ＭｃＡｂ与ＴＰＯＡｂ结合率的测定值呈显著相关（ｒ＝０．７３，Ｐ＜０．００１）；稀释试验提示ＭｃＡｂ可与ｈＴＰＤ结合且存在剂量依赖性。因此ＡＩＴＤ患者的ＭｃＡｂ所针对的微粒体抗原即为ｈＴＰＯ，而ＭｃＡｂ即为ＴＰＯＡｂ。
The hTPO was purified from the thyroid cell membrane components by sodium cholate solubilization, ammonium sulfate salting-out, differential centrifugation and immunoaffinity chromatography. The purified hTPO had a 438.7-fold increase in bioactivity and a RZ value of 0.25 . SDS-PAGE showed two bands at 105KD and 107KD. The solid-phase Iodogen method was used to label hTPO. The radioimmunoassay method was used to determine the binding rate of TPOAb in McAb positive serum of 29 patients with AITD (16.3% ± 6.3%), while the positive rate of McAb positive serum in 11 healthy people was 3.4% 14.7%. There was a significant correlation between McAb and TPOAb binding rate (r = 0.73, P <0.001). Dilution test indicated that McAb could bind to hTPD in a dose-dependent manner. Therefore, the AITD patients McAb against microsomal antigen that is hTPO, and McAb is TPOAb.